{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T23:03:40Z","timestamp":1762643020850,"version":"3.41.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>In this review, the authors discuss the use of stereotactic body radiation therapy (SBRT) for the treatment of primary and metastatic renal cell carcinoma (RCC).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>For primary RCC treated with SBRT, local control is estimated at &gt;95%, and grade 3\u20134 toxicity is limited at \u22645%. The difference in glomerular filtration rate pretreatment versus posttreatment was about 7.7\u00a0ml\/min. For metastatic RCC treated with SBRT, the 1-year local control is ~90%. The incidence of any grade 3\u20134 toxicity is ~1%. Several ongoing trials are evaluating SBRT in combination or in lieu of systemic therapy. There are many unknowns remaining in the treatment of RCC, including tumor prognostication, treatment selection, and treatment delivery.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Stereotactic body radiation therapy is a safe and effective treatment option for patients with primary and metastatic RCC.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/spc.0000000000000683","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T16:01:06Z","timestamp":1707753666000},"page":"308-314","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Radiation therapy options in kidney cancer"],"prefix":"10.1097","volume":"17","author":[{"given":"Nicholas G.","family":"Zaorsky","sequence":"first","affiliation":[{"name":"University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander V.","family":"Louie","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Odette Cancer Centre \u2013 Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shankar","family":"Siva","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,10,26]]},"reference":[{"key":"R1-20250525","doi-asserted-by":"crossref","first-page":"13862","DOI":"10.1038\/s41598-020-70840-2","article-title":"The burden of kidney cancer and its attributable risk factors in 195 countries and territories, 1990-2017","volume":"10","author":"Safiri","year":"2020","journal-title":"Sci Rep"},{"key":"R2-20250525","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1001\/jamaoncol.2015.0735","article-title":"The Global Burden of Cancer 2013","volume":"1","author":"Fitzmaurice","year":"2015","journal-title":"JAMA Oncol"},{"key":"R4-20250525","doi-asserted-by":"crossref","first-page":"71","DOI":"10.6004\/jnccn.2022.0001","article-title":"Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Motzer","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"R5-20250525","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1200\/JCO.22.00868","article-title":"Management of metastatic clear cell renal cell carcinoma: ASCO Guideline","volume":"40","author":"Rathmell","year":"2022","journal-title":"J Clin Oncol"},{"key":"R6-20250525","doi-asserted-by":"crossref","first-page":"69","DOI":"10.7326\/M17-0585","article-title":"Percutaneous ablation versus partial and radical nephrectomy for T1a renal cancer: a population-based analysis","volume":"169","author":"Talenfeld","year":"2018","journal-title":"Ann Intern Med"},{"key":"R7-20250525","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer Statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"R8-20250525","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1200\/JCO.2009.22.4816","article-title":"Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram","volume":"28","author":"Kutikov","year":"2010","journal-title":"J Clin Oncol"},{"key":"R9-20250525","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.juro.2012.03.006","article-title":"Comparative effectiveness for survival and renal function of partial and radical nephrectomy for localized renal tumors: a systematic review and meta-analysis","volume":"188","author":"Kim","year":"2012","journal-title":"J Urol"},{"key":"R10-20250525","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"R11-20250525","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/0360-3016(87)90283-5","article-title":"Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group","volume":"13","author":"Kjaer","year":"1987","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R12-20250525","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1093\/annonc\/mdq028","article-title":"Need for a new trial to evaluate postoperative radiotherapy in renal cell carcinoma: a meta-analysis of randomized controlled trials","volume":"21","author":"Tunio","year":"2010","journal-title":"Ann Oncol"},{"key":"R13-20250525","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3389\/fonc.2012.00104","article-title":"In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer","volume":"2","author":"Kwilas","year":"2012","journal-title":"Front Oncol"},{"key":"R14-20250525","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ijrobp.2009.09.042","article-title":"American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy","volume":"76","author":"Potters","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R15-20250525","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nrurol.2017.87","article-title":"Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach","volume":"14","author":"Siva","year":"2017","journal-title":"Nat Rev Urol"},{"key":"R16-20250525","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1038\/s41591-018-0232-2","article-title":"Radiotherapy induces responses of lung cancer to CTLA-4 blockade","volume":"24","author":"Formenti","year":"2018","journal-title":"Nat Med"},{"key":"R17-20250525","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1158\/0008-5472.CAN-10-2820","article-title":"The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity","volume":"71","author":"Burnette","year":"2011","journal-title":"Cancer Res"},{"key":"R18-20250525","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","article-title":"STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors","volume":"41","author":"Deng","year":"2014","journal-title":"Immunity"},{"key":"R19-20250525","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic correlates of the abscopal effect in a patient with melanoma","volume":"366","author":"Postow","year":"2012","journal-title":"N Engl J Med"},{"key":"R20-20250525","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S1470-2045(09)70082-8","article-title":"Systemic effects of local radiotherapy","volume":"10","author":"Formenti","year":"2009","journal-title":"Lancet Oncol"},{"key":"R21-20250525","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.3390\/ijms19103054","article-title":"Stereotactic radiosurgery and immune checkpoint inhibitors in the management of brain metastases","volume":"19","author":"Lehrer","year":"2018","journal-title":"Int J Mol Sci"},{"key":"R22-20250525","first-page":"S140","article-title":"Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: an international meta-analysis of individual patient data","volume":"102","author":"Lehrer","year":"2018","journal-title":"Radiother Oncol"},{"key":"R23-20250525","doi-asserted-by":"crossref","first-page":"5055","DOI":"10.1158\/1078-0432.CCR-16-2946","article-title":"A pilot study of stereotactic body radiation therapy combined with cytoreductive nephrectomy for metastatic renal cell carcinoma","volume":"23","author":"Singh","year":"2017","journal-title":"Clin Cancer Res"},{"key":"R24-20250525","doi-asserted-by":"crossref","first-page":"96","DOI":"10.21037\/apm.2017.03.06","article-title":"Stereotactic body radiation therapy for metastases to the kidney in patients with non-small cell lung cancer: a new treatment paradigm for durable palliation","volume":"6","author":"Verma","year":"2017","journal-title":"Ann Palliat Med"},{"key":"R25-20250525","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/cncr.31156","article-title":"Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: a report from the International Radiosurgery Oncology Consortium for Kidney (IROCK)","volume":"124","author":"Siva","year":"2018","journal-title":"Cancer"},{"key":"R26-20250525","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S1470-2045(22)00656-8","article-title":"5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney)","volume":"23","author":"Siva","year":"2022","journal-title":"Lancet Oncol"},{"key":"R27-20250525","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.euf.2019.06.002","article-title":"The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis","volume":"5","author":"Correa","year":"2019","journal-title":"Eur Urol Focus"},{"key":"R28-20250525","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2215\/CJN.11941116","article-title":"Renal functional outcomes after surgery, ablation, and active surveillance of localized renal tumors: a systematic review and meta-analysis","volume":"12","author":"Patel","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"R29-20250525","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.euo.2019.05.007","article-title":"Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies","volume":"2","author":"Zaorsky","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"R30-20250525","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/S1470-2045(21)00528-3","article-title":"Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial","volume":"22","author":"Tang","year":"2021","journal-title":"Lancet Oncol"},{"key":"R31-20250525","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.euo.2022.06.008","article-title":"Stereotactic ablative radiation for systemic therapy-naive oligometastatic kidney cancer","volume":"5","author":"Hannan","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"R32-20250525","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.eururo.2021.07.026","article-title":"Stereotactic radiotherapy for oligoprogression in metastatic renal cell cancer patients receiving tyrosine kinase inhibitor therapy: a phase 2 prospective multicenter study","volume":"80","author":"Cheung","year":"2021","journal-title":"Eur Urol"},{"key":"R33-20250525","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.eururo.2021.12.006","article-title":"Stereotactic radiotherapy and short-course pembrolizumab for oligometastatic renal cell carcinoma-The RAPPORT Trial","volume":"81","author":"Siva","year":"2022","journal-title":"Eur Urol"},{"key":"R34-20250525","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.radonc.2020.07.035","article-title":"Toxicity in combination immune checkpoint inhibitor and radiation therapy: a systematic review and meta-analysis","volume":"151","author":"Sha","year":"2020","journal-title":"Radiother Oncol"},{"key":"R35-20250525","doi-asserted-by":"crossref","first-page":"pkab050","DOI":"10.1093\/jncics\/pkab050","article-title":"Radiotherapy and receptor tyrosine kinase inhibition for solid cancers (ROCKIT): a meta-analysis of 13 studies","volume":"5","author":"Tchelebi","year":"2021","journal-title":"JNCI Cancer Spectr"},{"key":"R36-20250525","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ctrv.2016.11.013","article-title":"Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: a systematic review","volume":"53","author":"Kroeze","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"R37-20250525","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.ijrobp.2022.06.095","article-title":"Local treatment of the primary tumor for patients with metastatic cancer (PRIME-TX): a meta-analysis","volume":"114","author":"Ryckman","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R38-20250525","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/ijc.33744","article-title":"Pan-cancer analysis of prognostic metastatic phenotypes","volume":"150","author":"Zaorsky","year":"2022","journal-title":"Int J Cancer"}],"container-title":["Current Opinion in Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/SPC.0000000000000683","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T18:03:19Z","timestamp":1748196199000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/SPC.0000000000000683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,26]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/spc.0000000000000683","relation":{},"ISSN":["1751-4258"],"issn-type":[{"type":"print","value":"1751-4258"}],"subject":[],"published":{"date-parts":[[2023,10,26]]}}}